41 / 88
41
Tuesday, 20 June 2017
/ Scientific Programme
WFSBP 2017
TUE
T51: MISCELLANEOUS
WS-08
WORKSHOP
11:15–12:45
B3 M3-M4
Functional neuroanatomy of hallucinations
Chair:
Rajesh Nagpal, India
Co-Chair: Harishchandra Gambheera, Sri Lanka
001
Functional neuroanatomy of auditory hallu-
cinations
E. Mohandas Warrier, India
002
Neural signature of visual hallucinations
Venu Gopal Jhanwar, India
003
Neural mechanisms of somatic, musical and
extracampine hallucinations
Anukant Mital, India
004
The neural signature overlap between delusions
and hallucinations
Debashis Ray, India
P-06
POSTER TOUR
13:00–14:30
Congress Hall A 1
Depression 2
Chair:
Poul Videbech, Denmark
003
Early Serum-BDNF-Increase is facilitated by aero-
bic exercise and associated with lower insomnia severity
after 6 weeks of inpatient treatment for depression
Christian Imboden, Switzerland
J. Beck, M. Gerber, A. Eckert, U. Pühse, E. Holsboer-
Trachsler, M. Hatzinger
005
Effects of the adenosine A(1) receptor neurotrans-
mission on hyper-emotionality of olfactory bulbecto-
mized rat
Yuma Ogushi, Japan
L. Gotoh, K. Kira, T. Kawaguchi, A. Hatanaka,
H. Kawasaki
007
Risk markers for recurrence in major depression
Marcus Ising, Germany
P. Belcredi, S. Scheuer, M. Wierzyk, M. Uhr, S. Lucae,
F. Holsboer
008
Attenuation of deficits in behaviour and microglia
population in male high anxiety-related behaviour rats
by minocycline
Anna-Kristina Schmidtner, Germany
V. Malik, B. Di Benedetto, D. Slattery, I. Neumann
009
Hippocampal protein turnover alterations in
response to paroxetine treatment
Michaela Filiou, Germany
C. Webhofer, C. Guillermier, C. Poczatek, A. Chen,
C. Turck, C. Lechene
010
Positron emission tomography assessment of Keta-
mine binding on the Serotonin transporter in humans
Marie Spies, Austria
G. James, N. Berroterán Infante, H. Ibeschitz, J. Unter-
holzner, M. G. Godbersen, J. Jungwirth, M. Mitterhauser,
W. Wadsak, S. Kasper, R. Lanzenberger
011
A pharmacogenetic marker in DISP1 is not asso-
ciated with antidepressant response in obsessive-
compulsive disorder
Gwyneth Zai, Canada
A. Lisoway, K. Wigg, D. Zhang, N. Freeman, D. Mueller,
J. Kennedy, M. Richter
012
Vortioxetine for the treatment of depression:
A systematic review and meta-analysis
Chi-Un Pae, Republic of Korea
013
Correlations between middle-term outcome of
major depressive disorder and metabolic syndrome
Tudor Udristoiu, Romania
A. L. Chirita, F. Militaru, I. Udristoiu, S. Ristea
014
Effects of the proton pump inhibitors omeprazole
and pantoprazoleon the cytochrome P450 mediated
metabolism of Venlafaxine
Michael Paulzen, Germany
M. Kuzin, E. Haen, C. Hiemke, G. Gründer,
G. Schoretsanitis
015
Measures of daily mood, stress and reward
responses in offspring of depressed parents
Matthias Guillod, Switzerland
C. Gaillard, R. Recabarren, D. Schoebi, M. Merlo,
G. Hasler, C. Martin-Soelch
016
Does cortisol awakening response indicate the
impact of poor sleep on next day's negative affect?: An
event sampling study on major depression and controls
Thorsten Mikoteit, Switzerland
C. Imboden, F. Maier, M. Hatzinger, E. Holsboer-Trachsler,
R. Lieb, A. Gloster
017
Evaluation of affective temperaments, depression
and anxiety in different hypertensive conditions
Xénia Gonda, Hungary
D. Batta, B. Körösi, A. Lászlo, A. Tabák, D. Eörsi, P. Torzsa,
O. Cseprekal, A. Tisler, Z. Nemcsik-Bencze, Z. Rihmer,
J. Nemcsik